Group 1: Company Overview - Suning Universal Co., Ltd. focuses on real estate development and sales, pursuing a dual business strategy in real estate and medical aesthetics [2][3] - The company adheres to a "low debt, high return" operational strategy, emphasizing sustainable development [3] Group 2: Real Estate Business Performance - In 2025, the real estate sector remains under pressure, but the company has over 30 years of experience, enabling strong strategic decision-making [3] - The total land reserve is approximately 155 million square meters, primarily located in economically developed areas of the Yangtze River Delta, providing a significant competitive advantage [3] - The company's asset-liability ratio is 29.74%, with a net asset-liability ratio of 27.43%, indicating a solid financial foundation [5] Group 3: Medical Aesthetics Business - The company has established 7 medical aesthetics institutions, with the new Wuxi Suya Medical Aesthetics center already in trial operation [3][4] - In the first half of 2025, pre-receipts for Suya Medical Aesthetics reached 92.829 million yuan, a year-on-year increase of 18% [3] Group 4: Future Development Plans - The company plans to expand its medical aesthetics business through self-built stores and acquisitions, focusing on biomedicine and anti-aging [4] - By 2026, the revenue share from the medical aesthetics sector is expected to significantly increase as new institutions become operational [4] Group 5: Shareholder Returns - The company has consistently prioritized shareholder returns, with total cash dividends amounting to 966 million yuan since 2022, maintaining a high dividend yield [6] Group 6: Strategic Outlook - The company aims to drive growth through its dual business model, leveraging stable cash flow from real estate to expand medical aesthetics revenue [7] - There is an ongoing focus on high-tech industries and new business opportunities to optimize the company's operational structure [7]

Group 1: Company Overview and Strategy - The company focuses on real estate development and sales, with a strong presence in the Yangtze River Delta region, adhering to a "long-termism" philosophy and a strategy of "steady operation and progress" [2][3] - The company maintains a "low debt, high return" operational strategy while advancing its dual business model in real estate and medical aesthetics [2][3] Group 2: Real Estate Business Performance - The real estate sector remains under pressure, but market sales data is stabilizing; the company benefits from ample quality land reserves and low land costs, with a total land reserve of over 1.7 million square meters [3] - Key projects like Binjiang Yayuan and Rongjin Ruifu are performing well, with strong sales and high profitability [3][4] Group 3: Future Development Plans in Real Estate - The company plans to continue its high-profit and positive cash flow real estate projects, with new projects set to launch in advantageous areas in the second half of the year [4] - The company will focus on upgrading and launching premium projects while maintaining a stable pricing system [4] Group 4: Medical Aesthetics Business Performance - The company has established six medical aesthetics institutions, creating a distribution pattern across six cities, and is committed to compliance and quality management [5][6] - The revenue and profit from the medical aesthetics sector are gradually increasing, with expectations for significant growth in revenue share by 2026 as new institutions open in the Yangtze River Delta [6] Group 5: Market Conditions and Future Outlook for Medical Aesthetics - The medical aesthetics market is experiencing a slowdown, with increased concentration and the exit of smaller players; however, the company focuses on high-end clientele and maintains a stable pricing strategy [7][8] - The company aims to expand its medical aesthetics business while exploring new industries and opportunities for sustainable growth [8]